Research programme: enzyme inhibitors - Lixte Biotechnology Holdings

Drug Profile

Research programme: enzyme inhibitors - Lixte Biotechnology Holdings

Alternative Names: Cancer therapeutics - Lixte; LB-1.2; LB-102; LB-2.1; LB-200 series - Lixte; LB-201; LB-205; LB-300 series - Lixte; LB-400 series - Lixte; Neurological therapeutics - Lixte

Latest Information Update: 30 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Lixte Biotechnology Holdings
  • Developer Lixte Biotechnology Holdings; National Institute of Neurological Disorders and Stroke; National Institutes of Health (USA)
  • Class Antineoplastics; Cycloheptanes; Neuroprotectants; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors; Phosphoprotein phosphatase inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Gaucher's disease; Mycoses
  • Research Amyotrophic lateral sclerosis; Neurological disorders

Most Recent Events

  • 29 Mar 2017 Lixte Biotechnology Holdings has patent protection for LB 200 series compounds for the treatment of cancer in Australia, Canada, China, Japan, Mexico, USA and Eurasia
  • 29 Mar 2017 Lixte Biotechnology Holdings has patent protection for LB-100 series compounds for the treatment of cancer in Europe, Australia, China, Japan, Hong Kong, Mexico, USA and Eurasia
  • 29 Mar 2017 Lixte Biotechnology Holdings has patent protection for LB-200 and LB-100 series compounds for the prevention and treatment of Neurodegenerative disorders in USA and Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top